Ustekinumab for the treatment of psoriatic arthritis: An update

Parastoo Davari, Michael S. Leo, Faranak Kamangar, Nasim Fazel

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.

Original languageEnglish (US)
Pages (from-to)243-249
Number of pages7
JournalClinical, Cosmetic and Investigational Dermatology
StatePublished - Sep 2 2014


  • Psoriasis
  • Psoriatic arthritis
  • Ustekinumab

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Ustekinumab for the treatment of psoriatic arthritis: An update'. Together they form a unique fingerprint.

Cite this